As a reminder, Harvard Pilgrim does not cover the following Anser tests, which are conducted to measure serum levels of infliximab and antibodies to infliximab:
- Anser IFX
- Anser UST
- Anser VDZ
Harvard Pilgrim regularly reviews published medical and scientific literature to determine clinical appropriateness. Based on this ongoing review, these tests are considered experimental/investigational because literature does not support their safety and/or efficacy. These tests have been added to Harvard Pilgrim’s New Technology Assessment and Non-Covered Services Medical Policy.